ICCC

ImmuCell is a genuine operational turnaround inside a tiny, defensible niche. The headline isn't revenue — product sales rose only 4.3% to $27.6M despite manufacturing capacity expanding from 4.1M to 4.6M units — it's profitability quality. Gross margin jumped from 30% to 41% as COGS fell 13%, gross profit grew 44% to $11.4M, and the company swung to a positive operating income of $1.65M from a $1.64M loss. Operating cash flow surged ~592% to $2.48M, comfortably funding the $1.25M of capex. The reported -$1.04M net loss is misleading on its own: it is driven mainly by a $2.7M non-cash impairment booked when management paused the long-running, never-commercialized Re-Tain program in December 2025 to concentrate on First Defense. Stripping that, the underlying business is at or near breakeven and improving.

The balance sheet supports patience. Equity is $27.1M against $15.5M of liabilities (0.57x), current assets of $16.9M cover current liabilities of $3.98M more than 4x, and total debt (~$9.1M) is being paid down (long-term debt -17%). Dilution is negligible (+0.7%, 9.05M shares). The Re-Tain pivot removes a chronic cash drain and lets a new CEO/CFO focus the company on a product that prevents a disease responsible for 30-40% of pre-weaning calf mortality — a real, recurring, biologically-driven demand base. Eliminating the contamination backlog by June 2025 also removes a prior overhang.